A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure.

MLA

Massarweh, Suleiman, et al. “A Phase II Study of Combined Fulvestrant and Everolimus in Patients with Metastatic Estrogen Receptor (ER)-Positive Breast Cancer after Aromatase Inhibitor (AI) Failure.” Breast Cancer Research and Treatment, vol. 143, no. 2, Jan. 2014, pp. 325–32. EBSCOhost, https://doi.org/10.1007/s10549-013-2810-9.

APA

Massarweh, S., Romond, E., Black, E. P., Van Meter, E., Shelton, B., Kadamyan-Melkumian, V., Stevens, M., & Elledge, R. (2014). A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure. Breast Cancer Research and Treatment, 143(2), 325–332. https://doi.org/10.1007/s10549-013-2810-9

Chicago

Massarweh, Suleiman, Edward Romond, Esther P Black, Emily Van Meter, Brent Shelton, Vera Kadamyan-Melkumian, Mark Stevens, and Richard Elledge. 2014. “A Phase II Study of Combined Fulvestrant and Everolimus in Patients with Metastatic Estrogen Receptor (ER)-Positive Breast Cancer after Aromatase Inhibitor (AI) Failure.” Breast Cancer Research and Treatment 143 (2): 325–32. doi:10.1007/s10549-013-2810-9.